SK167997A3 - Cell line producing analgesic compounds for treating pain - Google Patents

Cell line producing analgesic compounds for treating pain Download PDF

Info

Publication number: SK167997A3
Authority: SK; Slovakia
Prior art keywords: sequence; cells; cell; ires; dna
Prior art date: 1995-06-07

Application number

SK1679-97A

Other languages

English (en)

Slovak (sk)

Inventor

Joel Saydoff

Shou Wong

Original Assignee

Cytotherapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-07

Publication date

1998-05-06

1996-06-07 Application filed by Cytotherapeutics Inc filed Critical Cytotherapeutics Inc

1998-05-06 Publication of SK167997A3 publication Critical patent/SK167997A3/sk

Links

208000002193 Pain Diseases 0.000 title claims abstract description 27
230000036407 pain Effects 0.000 title claims abstract description 21
230000000202 analgesic effect Effects 0.000 title claims description 31
150000001875 compounds Chemical class 0.000 title claims description 27
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims abstract description 26
150000003943 catecholamines Chemical class 0.000 claims abstract description 26
108010049140 Endorphins Proteins 0.000 claims abstract description 23
102000009025 Endorphins Human genes 0.000 claims abstract description 23
210000000056 organ Anatomy 0.000 claims abstract description 12
238000011282 treatment Methods 0.000 claims abstract description 7
108020004414 DNA Proteins 0.000 claims description 49
102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 44
239000013598 vector Substances 0.000 claims description 40
230000014509 gene expression Effects 0.000 claims description 39
238000000034 method Methods 0.000 claims description 34
108010092674 Enkephalins Proteins 0.000 claims description 26
239000012528 membrane Substances 0.000 claims description 26
108010041071 proenkephalin Proteins 0.000 claims description 21
229960002748 norepinephrine Drugs 0.000 claims description 20
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 20
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 19
YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 claims description 18
238000002513 implantation Methods 0.000 claims description 17
101800005049 Beta-endorphin Proteins 0.000 claims description 16
108010069820 Pro-Opiomelanocortin Proteins 0.000 claims description 16
WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 claims description 16
210000002330 subarachnoid space Anatomy 0.000 claims description 16
102400000988 Met-enkephalin Human genes 0.000 claims description 15
108010042237 Methionine Enkephalin Proteins 0.000 claims description 15
102000012582 Proenkephalin A Human genes 0.000 claims description 14
239000007943 implant Substances 0.000 claims description 13
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 10
210000003169 central nervous system Anatomy 0.000 claims description 6
229960003638 dopamine Drugs 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims description 5
102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims description 5
229920012196 Polyoxymethylene Copolymer Polymers 0.000 claims description 5
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 4
229930182837 (R)-adrenaline Natural products 0.000 claims description 4
102100025841 Cholecystokinin Human genes 0.000 claims description 4
229940107137 cholecystokinin Drugs 0.000 claims description 4
229960005139 epinephrine Drugs 0.000 claims description 4
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 4
101800001982 Cholecystokinin Proteins 0.000 claims description 3
101710151321 Melanostatin Proteins 0.000 claims description 3
102400000064 Neuropeptide Y Human genes 0.000 claims description 3
102400001103 Neurotensin Human genes 0.000 claims description 3
101800001814 Neurotensin Proteins 0.000 claims description 3
102000005157 Somatostatin Human genes 0.000 claims description 3
108010056088 Somatostatin Proteins 0.000 claims description 3
PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 claims description 3
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
229960000553 somatostatin Drugs 0.000 claims description 3
102400001370 Galanin Human genes 0.000 claims description 2
101800002068 Galanin Proteins 0.000 claims description 2
SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims description 2
102400000748 Beta-endorphin Human genes 0.000 claims 1
102000053602 DNA Human genes 0.000 claims 1
230000001131 transforming effect Effects 0.000 claims 1
210000004027 cell Anatomy 0.000 description 175
108090000623 proteins and genes Proteins 0.000 description 56
239000013612 plasmid Substances 0.000 description 51
108091034117 Oligonucleotide Proteins 0.000 description 47
239000012634 fragment Substances 0.000 description 40
108091028043 Nucleic acid sequence Proteins 0.000 description 37
230000000692 anti-sense effect Effects 0.000 description 35
108020004707 nucleic acids Proteins 0.000 description 30
102000039446 nucleic acids Human genes 0.000 description 30
150000007523 nucleic acids Chemical class 0.000 description 30
239000013615 primer Substances 0.000 description 25
239000000047 product Substances 0.000 description 23
239000000243 solution Substances 0.000 description 23
239000002299 complementary DNA Substances 0.000 description 22
239000013604 expression vector Substances 0.000 description 21
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 20
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 19
239000000835 fiber Substances 0.000 description 18
210000001519 tissue Anatomy 0.000 description 17
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 16
238000006243 chemical reaction Methods 0.000 description 15
230000004927 fusion Effects 0.000 description 15
239000000203 mixture Substances 0.000 description 15
239000000683 Pro-Opiomelanocortin Substances 0.000 description 14
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
239000011541 reaction mixture Substances 0.000 description 14
230000015572 biosynthetic process Effects 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 13
239000002773 nucleotide Substances 0.000 description 13
101800000414 Corticotropin Proteins 0.000 description 12
238000010276 construction Methods 0.000 description 12
239000000499 gel Substances 0.000 description 12
235000015097 nutrients Nutrition 0.000 description 12
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 11
230000003321 amplification Effects 0.000 description 11
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 11
229960000258 corticotropin Drugs 0.000 description 11
230000000694 effects Effects 0.000 description 11
239000012510 hollow fiber Substances 0.000 description 11
239000002609 medium Substances 0.000 description 11
238000003199 nucleic acid amplification method Methods 0.000 description 11
150000001413 amino acids Chemical class 0.000 description 10
230000029087 digestion Effects 0.000 description 10
229920001296 polysiloxane Polymers 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
108020005345 3' Untranslated Regions Proteins 0.000 description 9
108020003589 5' Untranslated Regions Proteins 0.000 description 9
102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 9
108010035075 Tyrosine decarboxylase Proteins 0.000 description 9
210000004556 brain Anatomy 0.000 description 9
239000002243 precursor Substances 0.000 description 9
238000000746 purification Methods 0.000 description 9
230000004044 response Effects 0.000 description 9
101150076211 TH gene Proteins 0.000 description 8
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
101150093308 POMC gene Proteins 0.000 description 7
108010002822 Phenylethanolamine N-Methyltransferase Proteins 0.000 description 7
102100028917 Phenylethanolamine N-methyltransferase Human genes 0.000 description 7
230000036592 analgesia Effects 0.000 description 7
210000003737 chromaffin cell Anatomy 0.000 description 7
238000003776 cleavage reaction Methods 0.000 description 7
238000004925 denaturation Methods 0.000 description 7
230000036425 denaturation Effects 0.000 description 7
238000005538 encapsulation Methods 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
230000007017 scission Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
229920000936 Agarose Polymers 0.000 description 6
108091026890 Coding region Proteins 0.000 description 6
108010093625 Opioid Peptides Proteins 0.000 description 6
102000001490 Opioid Peptides Human genes 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000001919 adrenal effect Effects 0.000 description 6
239000002775 capsule Substances 0.000 description 6
239000013599 cloning vector Substances 0.000 description 6
239000011162 core material Substances 0.000 description 6
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 6
239000003399 opiate peptide Substances 0.000 description 6
229920002239 polyacrylonitrile Polymers 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
238000011160 research Methods 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 5
241000283690 Bos taurus Species 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
108090000137 Opioid Receptors Proteins 0.000 description 5
102000003840 Opioid Receptors Human genes 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
239000011543 agarose gel Substances 0.000 description 5
229940035676 analgesics Drugs 0.000 description 5
239000000730 antalgic agent Substances 0.000 description 5
210000001175 cerebrospinal fluid Anatomy 0.000 description 5
238000010367 cloning Methods 0.000 description 5
230000000295 complement effect Effects 0.000 description 5
238000005336 cracking Methods 0.000 description 5
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
239000000017 hydrogel Substances 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
210000000278 spinal cord Anatomy 0.000 description 5
238000013519 translation Methods 0.000 description 5
238000011144 upstream manufacturing Methods 0.000 description 5
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
208000000094 Chronic Pain Diseases 0.000 description 4
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
241000620209 Escherichia coli DH5[alpha] Species 0.000 description 4
241000589500 Thermus aquaticus Species 0.000 description 4
108010084455 Zeocin Proteins 0.000 description 4
239000000853 adhesive Substances 0.000 description 4
230000001070 adhesive effect Effects 0.000 description 4
229940072056 alginate Drugs 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 4
101150109673 dbh gene Proteins 0.000 description 4
210000003195 fascia Anatomy 0.000 description 4
229960003692 gamma aminobutyric acid Drugs 0.000 description 4
238000010353 genetic engineering Methods 0.000 description 4
URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 4
210000004749 ligamentum flavum Anatomy 0.000 description 4
210000004705 lumbosacral region Anatomy 0.000 description 4
229960005181 morphine Drugs 0.000 description 4
230000003040 nociceptive effect Effects 0.000 description 4
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
239000003155 DNA primer Substances 0.000 description 3
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
102400000243 Leu-enkephalin Human genes 0.000 description 3
108010022337 Leucine Enkephalin Proteins 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
102100038931 Proenkephalin-A Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
206010052779 Transplant rejections Diseases 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
108010006886 Vitrogen Proteins 0.000 description 3
230000004913 activation Effects 0.000 description 3
210000004100 adrenal gland Anatomy 0.000 description 3
230000000735 allogeneic effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
102000005396 glutamine synthetase Human genes 0.000 description 3
108020002326 glutamine synthetase Proteins 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
239000010410 layer Substances 0.000 description 3
WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
239000002808 molecular sieve Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
230000008533 pain sensitivity Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
229920000915 polyvinyl chloride Polymers 0.000 description 3
239000004800 polyvinyl chloride Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000007789 sealing Methods 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
241000894007 species Species 0.000 description 3
238000012360 testing method Methods 0.000 description 3
239000010936 titanium Substances 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
101100352762 Drosophila melanogaster pnut gene Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
241000282412 Homo Species 0.000 description 2
101001099423 Homo sapiens Proenkephalin-A Proteins 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
102400000747 Melanocyte-stimulating hormone beta Human genes 0.000 description 2
101710129905 Melanotropin beta Proteins 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
241000288906 Primates Species 0.000 description 2
102000006437 Proprotein Convertases Human genes 0.000 description 2
108010044159 Proprotein Convertases Proteins 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
101100101253 Rattus norvegicus Th gene Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
239000003522 acrylic cement Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
208000005298 acute pain Diseases 0.000 description 2
230000001800 adrenalinergic effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000001851 biosynthetic effect Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000003164 cauda equina Anatomy 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000011109 contamination Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
239000005546 dideoxynucleotide Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
238000002594 fluoroscopy Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
229940039009 isoproterenol Drugs 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000002756 mu opiate receptor agonist Substances 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
229920002492 poly(sulfone) Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000004814 polyurethane Substances 0.000 description 2
229920002635 polyurethane Polymers 0.000 description 2
229920000131 polyvinylidene Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 2
229960004617 sapropterin Drugs 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002689 soil Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
239000006163 transport media Substances 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
101100499810 Bos taurus DBH gene Proteins 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
HQOWCDPFDSRYRO-CDKVKFQUSA-N CCCCCCc1ccc(cc1)C1(c2cc3-c4sc5cc(\C=C6/C(=O)c7ccccc7C6=C(C#N)C#N)sc5c4C(c3cc2-c2sc3cc(C=C4C(=O)c5ccccc5C4=C(C#N)C#N)sc3c12)(c1ccc(CCCCCC)cc1)c1ccc(CCCCCC)cc1)c1ccc(CCCCCC)cc1 Chemical compound CCCCCCc1ccc(cc1)C1(c2cc3-c4sc5cc(\C=C6/C(=O)c7ccccc7C6=C(C#N)C#N)sc5c4C(c3cc2-c2sc3cc(C=C4C(=O)c5ccccc5C4=C(C#N)C#N)sc3c12)(c1ccc(CCCCCC)cc1)c1ccc(CCCCCC)cc1)c1ccc(CCCCCC)cc1 HQOWCDPFDSRYRO-CDKVKFQUSA-N 0.000 description 1
102400000113 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000003670 Carboxypeptidase B Human genes 0.000 description 1
108090000087 Carboxypeptidase B Proteins 0.000 description 1
206010008164 Cerebrospinal fluid leakage Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
108700022182 D-Penicillamine (2,5)- Enkephalin Proteins 0.000 description 1
MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 1
102100024746 Dihydrofolate reductase Human genes 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
241001269524 Dura Species 0.000 description 1
108010065372 Dynorphins Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
102100026693 FAS-associated death domain protein Human genes 0.000 description 1
108090001053 Gastrin releasing peptide Proteins 0.000 description 1
102000004862 Gastrin releasing peptide Human genes 0.000 description 1
206010060891 General symptom Diseases 0.000 description 1
101100384385 Homo sapiens CNTF gene Proteins 0.000 description 1
101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 1
101100007236 Homo sapiens POMC gene Proteins 0.000 description 1
208000004454 Hyperalgesia Diseases 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
241000234435 Lilium Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
101710200814 Melanotropin alpha Proteins 0.000 description 1
YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 1
102400000992 Met-enkephalin-Arg-Gly-Leu Human genes 0.000 description 1
101800000700 Met-enkephalin-Arg-Gly-Leu Proteins 0.000 description 1
102400000987 Met-enkephalin-Arg-Phe Human genes 0.000 description 1
101800000666 Met-enkephalin-Arg-Phe Proteins 0.000 description 1
KTQKWSPZOZKAEE-LJADHVKFSA-N Met-enkephalin-Arg-Phe Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 KTQKWSPZOZKAEE-LJADHVKFSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010061310 Nerve root injury Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
101150012394 PHO5 gene Proteins 0.000 description 1
208000006735 Periostitis Diseases 0.000 description 1
108010002747 Pfu DNA polymerase Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102000012543 Proenkephalin B Human genes 0.000 description 1
102000004088 Proprotein Convertase 2 Human genes 0.000 description 1
108090000545 Proprotein Convertase 2 Proteins 0.000 description 1
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
101001077668 Rattus norvegicus Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
210000001943 adrenal medulla Anatomy 0.000 description 1
210000004079 adrenergic fiber Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
KWRGRUMGKJGCKH-OXQOHEQNSA-N allad Chemical compound C1=CC=C2C3=C[C@@H](C(=O)N(CC)CC)CN(CC=C)[C@@H]3CC3=CN=C1[C]32 KWRGRUMGKJGCKH-OXQOHEQNSA-N 0.000 description 1
108010041395 alpha-Endorphin Proteins 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
108010042362 beta-Lipotropin Proteins 0.000 description 1
230000008275 binding mechanism Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000011449 brick Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
108020001778 catalytic domains Proteins 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
GRFFKYTUNTWAGG-UHFFFAOYSA-N chloroethene;prop-2-enenitrile Chemical compound ClC=C.C=CC#N GRFFKYTUNTWAGG-UHFFFAOYSA-N 0.000 description 1
238000007813 chromatographic assay Methods 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000003131 corticotrophic effect Effects 0.000 description 1
229920003020 cross-linked polyethylene Polymers 0.000 description 1
239000004703 cross-linked polyethylene Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000007872 degassing Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
108700023159 delta Opioid Receptors Proteins 0.000 description 1
102000048124 delta Opioid Receptors Human genes 0.000 description 1
239000000841 delta opiate receptor agonist Substances 0.000 description 1
-1 derivatives Polymers 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000003890 endocrine cell Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000000375 enkephalinergic effect Effects 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
108010047064 gamma-Endorphin Proteins 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000012642 immune effector Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003140 lateral ventricle Anatomy 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000007726 management method Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
238000001690 micro-dialysis Methods 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
208000029986 neuroepithelioma Diseases 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
231100000878 neurological injury Toxicity 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
230000001129 nonadrenergic effect Effects 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000000406 opioidergic effect Effects 0.000 description 1
230000005305 organ development Effects 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
230000009996 pancreatic endocrine effect Effects 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
210000003460 periosteum Anatomy 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920005597 polymer membrane Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000026416 response to pain Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
229930000044 secondary metabolite Natural products 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002955 secretory cell Anatomy 0.000 description 1
235000008790 seltzer Nutrition 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
230000003238 somatosensory effect Effects 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
101150050282 ullA gene Proteins 0.000 description 1
244000239635 ulla Species 0.000 description 1
230000035899 viability Effects 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000003466 welding Methods 0.000 description 1
NXSIJWJXMWBCBX-NWKQFZAZSA-N α-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 NXSIJWJXMWBCBX-NWKQFZAZSA-N 0.000 description 1
GASYAMBJHBRTOE-WHDBNHDESA-N γ-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 GASYAMBJHBRTOE-WHDBNHDESA-N 0.000 description 1
108020001612 μ-opioid receptors Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/70—Enkephalins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Neurology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK1679-97A 1995-06-07 1996-06-07 Cell line producing analgesic compounds for treating pain SK167997A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48191795A	1995-06-07	1995-06-07
PCT/US1996/009629 WO1996040959A1 (en)	1995-06-07	1996-06-07	Cell line producing analgesic compounds for treating pain

Publications (1)

Publication Number	Publication Date
SK167997A3 true SK167997A3 (en)	1998-05-06

Family

ID=23913905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1679-97A SK167997A3 (en)	1995-06-07	1996-06-07	Cell line producing analgesic compounds for treating pain

Country Status (20)

Country	Link
EP (1)	EP0833935A1 (2)
JP (1)	JPH11507530A (2)
KR (1)	KR19990022414A (2)
CN (1)	CN1192246A (2)
AR (1)	AR004494A1 (2)
AU (1)	AU6263696A (2)
BR (1)	BR9608746A (2)
CA (1)	CA2223246A1 (2)
CZ (1)	CZ392497A3 (2)
EE (1)	EE9700326A (2)
HU (1)	HUP9901191A2 (2)
IL (1)	IL122415A0 (2)
IN (1)	IN181898B (2)
IS (1)	IS4628A (2)
NO (1)	NO975545L (2)
PL (1)	PL323867A1 (2)
SK (1)	SK167997A3 (2)
TR (1)	TR199701520T1 (2)
WO (1)	WO1996040959A1 (2)
ZA (1)	ZA964880B (2)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001525168A (ja) *	1997-11-28	2001-12-11	メディカルリサーチカウンシル	ベクター
AU6151899A (en)	1998-09-23	2000-04-10	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Methods of treating chronic pain
US6372489B1 (en)	1998-10-27	2002-04-16	Anticancer, Inc.	Method and model for hair pigmentation
WO2000024895A2 (en) *	1998-10-27	2000-05-04	Anticancer, Inc.	Method and model for hair pigmentation
US6903244B1 (en)	1999-02-26	2005-06-07	University Of Utah Research Foundation	Mice which are +/− or −/− for the elastin gene as models for vascular disease
AU2002952993A0 (en)	2002-11-29	2002-12-12	The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland	Therapeutic and diagnostic agents
WO2005060992A1 (en)	2003-12-24	2005-07-07	The Walter And Eliza Hall Institute Of Medical Research	Therapeutic agents and uses therefor
CA2566549C (en)	2004-05-12	2014-01-14	The Walter And Eliza Hall Institute Of Medical Research	A method for isolating mammary stem cells
DK2407484T3 (en)	2005-06-24	2016-09-05	The Walter And Eliza Hall Inst Of Medical Res	Therapeutic pro-apoptotic BH3-like molecules, and methods of generating and / or selecting those
JP5558817B2 (ja)	2006-07-18	2014-07-23	ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション	痛みの処置方法および鎮痛化合物のスクリーニング方法
US8889173B2 (en) *	2008-04-18	2014-11-18	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
CN105377286B (zh)	2013-05-31	2021-07-02	犹他大学研究基金会	芋螺毒素(conotoxin)肽，其医药组合物和用途
EP3368551B1 (en)	2015-10-27	2023-07-12	The University Of Queensland	A modified epha4 polypeptide
CN107964047B (zh) *	2017-12-18	2018-11-02	哈尔滨工业大学	基于内吗啡肽-1和神经降压素(8-13)的嵌合肽及其合成方法和应用
CN112891337A (zh) *	2021-03-26	2021-06-04	河北医科大学	高良姜素及其衍生物在制备预防和治疗神经系统疾病药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE218893T1 (de) *	1993-08-12	2002-06-15	Neurotech Sa	Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten

1996
- 1996-06-05 IN IN1039CA1996 patent/IN181898B/en unknown
- 1996-06-06 AR ARP960102993A patent/AR004494A1/es unknown
- 1996-06-07 JP JP9501908A patent/JPH11507530A/ja active Pending
- 1996-06-07 KR KR1019970708894A patent/KR19990022414A/ko not_active Withdrawn
- 1996-06-07 BR BR9608746A patent/BR9608746A/pt unknown
- 1996-06-07 SK SK1679-97A patent/SK167997A3/sk unknown
- 1996-06-07 WO PCT/US1996/009629 patent/WO1996040959A1/en not_active Ceased
- 1996-06-07 TR TR97/01520T patent/TR199701520T1/xx unknown
- 1996-06-07 EE EE9700326A patent/EE9700326A/xx unknown
- 1996-06-07 CA CA002223246A patent/CA2223246A1/en not_active Abandoned
- 1996-06-07 IL IL12241596A patent/IL122415A0/xx unknown
- 1996-06-07 CZ CZ973924A patent/CZ392497A3/cs unknown
- 1996-06-07 PL PL96323867A patent/PL323867A1/xx unknown
- 1996-06-07 ZA ZA964880A patent/ZA964880B/xx unknown
- 1996-06-07 AU AU62636/96A patent/AU6263696A/en not_active Abandoned
- 1996-06-07 EP EP96921403A patent/EP0833935A1/en not_active Withdrawn
- 1996-06-07 HU HU9901191A patent/HUP9901191A2/hu unknown
- 1996-06-07 CN CN96195750A patent/CN1192246A/zh active Pending
1997
- 1997-12-02 NO NO975545A patent/NO975545L/no unknown
- 1997-12-04 IS IS4628A patent/IS4628A/is unknown

Also Published As

Publication number	Publication date
PL323867A1 (en)	1998-04-27
WO1996040959A1 (en)	1996-12-19
AR004494A1 (es)	1998-12-16
IL122415A0 (en)	1998-06-15
HUP9901191A2 (hu)	1999-08-30
EE9700326A (et)	1998-06-15
EP0833935A1 (en)	1998-04-08
NO975545L (no)	1998-02-04
TR199701520T1 (xx)	1998-04-21
BR9608746A (pt)	1999-05-11
IN181898B (2)	1998-10-24
AU6263696A (en)	1996-12-30
JPH11507530A (ja)	1999-07-06
ZA964880B (en)	1997-01-07
CN1192246A (zh)	1998-09-02
NO975545D0 (no)	1997-12-02
IS4628A (is)	1997-12-04
CZ392497A3 (cs)	1998-12-16
KR19990022414A (ko)	1999-03-25
CA2223246A1 (en)	1996-12-19

Publication	Publication Date	Title
SK167997A3 (en)	1998-05-06	Cell line producing analgesic compounds for treating pain
AU669499B2 (en)	1996-06-13	Transfection of vertebrate cells e.g. by homologous recombination
AU697600B2 (en)	1998-10-08	Method for implanting encapsulated cells in a host
US20180177736A1 (en)	2018-06-28	Cell Lines and Their Use in Encapsulated Cell Biodelivery
JP4456275B2 (ja)	2010-04-28	細胞表面分子誘導性マクロファージ活性化
US20030031696A1 (en)	2003-02-13	Artificial salivary gland
JP6621420B2 (ja)	2019-12-18	糖尿病を治療するためのトランスジェニックブタ膵島およびその使用
DE69637185T2 (de)	2008-04-10	Isolierte Stromazellen und Methoden zu deren Verwendung
JP2017519483A5 (2)	2018-05-24
TWI284132B (en)	2007-07-21	Nucleic acid construct for optimized production of products
Christ	2003	Frontiers in gene therapy for erectile dysfunction
CA2285178A1 (en)	1998-10-01	Bone marrow as a site for transplantation
US20050260178A1 (en)	2005-11-24	Delivery of an organized tissue to an organism
CN1325650C (zh)	2007-07-11	猪促生长素传递系统
AU1005400A (en)	2000-05-11	Pain cell line
CN116135233A (zh)	2023-05-19	Cpe在制备促进原位神经发生及治疗衰老相关神经退行性疾病药物中的应用
AU4410799A (en)	1999-12-20	Prosthetic implant and methods of use for therapeutic gene expression
AU4734199A (en)	2000-02-03	Transfection of vertebrate cells e.g. by homologous recombination
AU1139300A (en)	2000-05-08	Delivery system for porcine somatotropin
HK1047296A (en)	2003-02-14	Transfection of vertebrate cells e.g. by homologous recombination